Aclarion Jumps 10% After Securing Full Funding For CLARITY Trial

(RTTNews) - Aclarion, Inc. (ACON) is up by 10 percent on Tuesday after announcing that it has secured full funding for its pivotal CLARITY trial.

ACON is currently trading at $7.16, up $0.51 from the previous close of $6.65. The stock has fluctuated today, reaching a high of $8.75 and a low of $6.75. Trading volume has surged to 6.61 million shares, significantly higher than the average volume of 185,599.

The trial aims to demonstrate the clinical and economic value of Nociscan, the company's AI-driven biomarker technology designed to help physicians identify the source of chronic low back pain.

The funding for the CLARITY trial marks a key step forward for Aclarion, as the company seeks to validate Nociscan's role in spine surgery decision-making.